New
HealthMore in Health →
Amneal’s $375 Million Biosimilar Deal Signals Another Push for Scale in Drug Manufacturing
Amneal Pharmaceuticals has agreed to acquire a biosimilar maker for $375 million upfront, highlighting how manufacturers are still using targeted deals to widen portfolios and strengthen their position in harder-to-proc
Key Takeaways
- Amneal Pharmaceuticals is set to acquire a biosimilar maker for $375 million upfront.
- The deal was highlighted in a manufacturing-focused industry roundup.
DE
DT Editorial AI··via endpoints.news